Compass Pathways Reports Six-Month Results Confirming Durable Benefits in Second Phase 3 Trial
Compass Pathways plc, a biotechnology company focused on developing evidence-based mental health treatments, has announced new 26-week (six-month) results from the ongoing Phase 3 COMP006 clinical trial evaluating COMP360, its proprietary synthetic psilocybin formulation, as a potential treatment for treatment-resistant depression (TRD). The latest findings reinforce earlier clinical evidence showing that the investigational therapy produces a rapid onset of antidepressant effects with benefits that can remain durable for at least six months in many patients.
The results, drawn from nearly 600 participants, build upon findings from the company’s first pivotal Phase 3 study, COMP005, which also demonstrated meaningful and sustained improvements in people living with chronic treatment-resistant depression. Together, the two large-scale Phase 3 trials strengthen the growing body of evidence supporting COMP360 as a potential new therapeutic option for individuals whose depression has not responded adequately to conventional antidepressant medications.
Compass Pathways stated that the new data will support its ongoing rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). The company expects to complete the regulatory submission during the fourth quarter of 2026 and, pending FDA approval and subsequent scheduling action by the U.S. Drug Enforcement Administration (DEA), anticipates a commercial launch during the first half of 2027.
Addressing an Urgent Need in Treatment-Resistant Depression
Major depressive disorder affects millions of people worldwide, and while antidepressant medications and psychotherapy are effective for many individuals, a significant proportion of patients do not experience adequate symptom relief despite multiple treatment attempts.
These individuals are often diagnosed with treatment-resistant depression, a condition typically defined as depression that fails to respond to at least two appropriate courses of antidepressant therapy.
Treatment-resistant depression is associated with:
- Persistent depressive symptoms
- Increased suicide risk
- Reduced quality of life
- Functional impairment
- Frequent healthcare utilization
- Greater economic burden
- Increased caregiver stress
Many patients remain symptomatic for years despite trying numerous medications, psychotherapy approaches, and other interventions.
As a result, there remains substantial interest in developing novel therapies capable of producing faster, more durable antidepressant effects than currently available treatment options.
COMP360: A Synthetic Psilocybin Therapy
COMP360 is Compass Pathways’ proprietary synthetic formulation of psilocybin, a naturally occurring psychedelic compound that has gained increasing scientific attention for its potential therapeutic applications in mental health disorders.
Unlike recreational use, COMP360 is administered within a carefully controlled clinical setting under professional supervision alongside structured psychological support.
The treatment model involves limited dosing sessions rather than daily medication.
Researchers believe this approach may produce sustained improvements in depressive symptoms following only one or a small number of treatment sessions.
The Phase 3 clinical program is evaluating whether this model can provide meaningful long-term benefits while maintaining an acceptable safety profile.
Understanding the COMP006 Trial
COMP006 represents the second ongoing Phase 3 clinical trial within Compass Pathways’ broader development program.
The study enrolled nearly 600 participants diagnosed with treatment-resistant depression.
Importantly, the trial population represented individuals with particularly severe and chronic illness.
According to Compass Pathways, participants experienced:
- Current depressive episodes lasting more than three years on average
- More than six lifetime depressive episodes on average
- Multiple previous treatment failures with conventional antidepressants
This patient population reflects individuals frequently encountered in real-world psychiatric practice who continue experiencing disabling depression despite extensive treatment histories.
Because these patients typically have poorer outcomes with standard therapies, demonstrating meaningful improvement in this population carries particular clinical significance.
Six-Month Results
The newly reported findings cover Part B of the COMP006 trial, evaluating outcomes through Week 26, approximately six months after treatment.
Among participants receiving the 25 mg dose of COMP360, investigators observed that:
- 39% achieved a clinically meaningful reduction in depressive symptoms by Week 6
- These improvements remained durable through at least Week 26
Clinical improvement was measured using the Montgomery-Åsberg Depression Rating Scale (MADRS), one of the most widely used standardized tools for assessing depression severity in clinical research.
A clinically meaningful response was defined as at least a 25% reduction in MADRS scores.
These sustained improvements suggest that therapeutic benefits extended well beyond the initial treatment period.
Comparing COMP006 and COMP005
The new results complement previously reported findings from the earlier COMP005 Phase 3 study.
In COMP005, approximately 25% of patients receiving a single dose of COMP360 achieved clinically meaningful improvement that persisted for at least six months.
In comparison, COMP006 evaluated a regimen involving two fixed doses.
The observed 39% response rate suggests that administering a second treatment session may enhance clinical benefit for certain patients.
Although direct comparisons between separate clinical trials should be interpreted cautiously, the consistency observed across both studies strengthens confidence in COMP360’s therapeutic profile.
Together, the two Phase 3 trials provide evidence supporting both rapid symptom improvement and sustained antidepressant effects.
Rapid Onset of Action
One characteristic attracting considerable attention is COMP360’s rapid onset.
Traditional antidepressants often require several weeks before patients experience meaningful improvement.
For individuals with severe treatment-resistant depression, these delays can prolong suffering and increase clinical risks.
In contrast, COMP360 has demonstrated measurable clinical improvement within the early weeks following treatment.
Rapid symptom reduction may prove especially valuable for patients experiencing prolonged depressive episodes that have persisted despite multiple previous therapies.
Earlier symptom improvement also has the potential to reduce functional impairment while supporting broader recovery efforts.
Durability of Clinical Benefit
Equally important is the durability observed following treatment.
Many antidepressant medications require continuous daily administration to maintain therapeutic effects.
Missed doses or medication discontinuation frequently lead to symptom recurrence.
COMP360 follows a different treatment paradigm.
Rather than requiring daily medication, therapeutic effects may persist for several months following limited supervised treatment sessions.
If confirmed through regulatory review and clinical practice, this approach could significantly alter long-term depression management.
Instead of ongoing daily medication, some patients might achieve sustained benefit after only a small number of annual treatments.
Safety Profile Remains Consistent
Compass Pathways also reported that COMP360 continued demonstrating a generally well-tolerated safety profile.
According to the company:
- Most treatment-emergent adverse events (TEAEs) were temporary.
- The majority occurred on the day treatment was administered.
- No unexpected safety concerns emerged during long-term follow-up.
Maintaining a consistent safety profile across multiple large Phase 3 studies represents an important aspect of regulatory evaluation.
Both efficacy and safety data will contribute to the FDA’s assessment during the NDA review process.
Rolling FDA Submission Underway
Compass Pathways has already begun submitting portions of its New Drug Application to the FDA through the agency’s rolling review process.
Rolling submissions allow companies to provide completed sections of an application before the entire dossier is finalized.
This process may facilitate more efficient regulatory review for eligible therapies.
The company stated that:
- Initial FDA review activities are underway.
- Final NDA submission remains on schedule for the fourth quarter of 2026.
- Commercial launch is anticipated during the first half of 2027 if regulatory approvals are obtained.
Because psilocybin remains a controlled substance, commercialization would also require DEA rescheduling following FDA approval.
Company Perspective
Compass Pathways Chief Executive Officer Kabir Nath described the COMP006 findings as an important milestone supporting completion of the regulatory submission.
According to Nath, the consistent demonstration of rapid symptom improvement together with durable clinical benefit strengthens confidence in COMP360’s therapeutic potential.
He suggested that the treatment could contribute to a meaningful shift in psychiatric care by moving away from models requiring daily medication toward treatment approaches involving only a limited number of supervised sessions annually.
Nath also expressed optimism regarding ongoing interactions with the FDA and the company’s preparations for potential commercialization in 2027.
Clinical Perspective
Chief Medical Officer Dr. Guy Goodwin emphasized that the Phase 3 participants reflected the realities of treatment-resistant depression encountered in everyday psychiatric practice.
Many patients had already failed multiple antidepressant regimens while experiencing depressive episodes lasting several years.
Goodwin noted that COMP360 consistently demonstrated:
- Rapid improvement
- Durable effects
- Reproducible outcomes
- Acceptable safety
across two large randomized Phase 3 studies.
He described these findings as particularly significant given the high degree of chronic illness and treatment resistance among participants.
According to Goodwin, successful outcomes in this challenging patient population could represent an important advancement in psychiatric treatment.
Independent Clinical Perspective
Dr. Tobias Marton, Chief Medical Officer at Mindful Health Solutions, also commented on the study findings.
He noted that his organization regularly treats patients with severe depression who have not responded adequately to conventional antidepressants.
Marton highlighted several aspects of the COMP006 results:
- Average depressive episode duration exceeded three years.
- Participants experienced more than six lifetime depressive episodes.
- Nearly 40% achieved meaningful clinical response following two doses.
- Responses remained durable for approximately six months.
- Nearly one-third of responders entered remission during the treatment interval.
He described these findings as an encouraging development that may expand treatment options for patients with some of the most difficult-to-treat forms of depression.
Potential Impact on Psychiatry
If approved, COMP360 would represent part of a broader evolution occurring within psychiatric medicine.
Researchers increasingly recognize that new therapeutic approaches may be necessary for patients who do not benefit from conventional antidepressants.
Novel treatments currently under investigation include:
- Psychedelic-assisted therapies
- NMDA receptor modulators
- Neurostimulation techniques
- Digital therapeutics
- Precision psychiatry approaches
The goal is to provide additional options tailored to different patient populations while improving long-term outcomes.
COMP360’s limited dosing schedule differs substantially from traditional antidepressant therapy and could introduce an alternative treatment model if approved by regulators.
The six-month results from the Phase 3 COMP006 trial further strengthen the clinical evidence supporting COMP360 as a potential treatment for individuals living with treatment-resistant depression. By demonstrating rapid symptom improvement, sustained therapeutic benefits lasting at least six months, and a generally favorable safety profile in a highly treatment-resistant patient population, the investigational therapy continues to show promise as a novel approach to managing one of psychiatry’s most challenging conditions.
With the FDA review process already underway and final regulatory submission expected later in 2026, Compass Pathways is moving closer to a potential approval decision. If the therapy receives authorization from the FDA and subsequent DEA rescheduling, COMP360 could become one of the first evidence-based psilocybin treatments available for treatment-resistant depression, potentially offering a new option for patients who have exhausted conventional therapies and reshaping expectations for the future of mental healthcare.
Source link: https://ir.compasspathways.com/
